LEXX vs. SAVA, MCRB, SLDB, JMAC, TCRX, BDTX, ANRO, ALGS, XBIT, and ZURA
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Cassava Sciences (SAVA), Seres Therapeutics (MCRB), Solid Biosciences (SLDB), Maxpro Capital Acquisition (JMAC), TScan Therapeutics (TCRX), Black Diamond Therapeutics (BDTX), Alto Neuroscience (ANRO), Aligos Therapeutics (ALGS), XBiotech (XBIT), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry.
Lexaria Bioscience vs.
Lexaria Bioscience (NASDAQ:LEXX) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.
Lexaria Bioscience has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.99, indicating that its stock price is 199% less volatile than the S&P 500.
Lexaria Bioscience currently has a consensus price target of $9.50, suggesting a potential upside of 421.98%. Cassava Sciences has a consensus price target of $111.50, suggesting a potential upside of 4,584.87%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Lexaria Bioscience.
Lexaria Bioscience has higher revenue and earnings than Cassava Sciences. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 26.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 9.0% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cassava Sciences received 91 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 65.33% of users gave Cassava Sciences an outperform vote.
In the previous week, Cassava Sciences had 15 more articles in the media than Lexaria Bioscience. MarketBeat recorded 24 mentions for Cassava Sciences and 9 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.33 beat Cassava Sciences' score of 0.08 indicating that Lexaria Bioscience is being referred to more favorably in the media.
Cassava Sciences has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,473.04%. Cassava Sciences' return on equity of -88.05% beat Lexaria Bioscience's return on equity.
Summary
Lexaria Bioscience beats Cassava Sciences on 9 of the 17 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:LEXX) was last updated on 1/30/2025 by MarketBeat.com Staff
